University of California, San Francisco (UCSF)
About University of California, San Francisco (UCSF)
Check out the link below for more information on biotechnolgy-related research at UCSF.575 articles with University of California, San Francisco (UCSF)
-
As the Trump administration has continued to show its lack of financial support of scientific research using fetal tissue, the National Institutes of Health is setting aside $20 million to fund research that could develop alternatives to the use of embryonic tissue.
-
Political Battle Over Fetal Tissue Could Force Closure of Research Center Pivotal to HIV Therapies
12/6/2018
Researchers who focus on HIV vaccines are caught in the middle of a political battle over funding of fetal stem cell research. -
New research is shedding some light on how the brain responds when people are feeling sad, which could lead to new methods of treating some mood disorders. A research team from the University of California, San Francisco (UCSF) reported in an article in Cell that a network defined by amygdala-hip...
-
Genentech, a Roche company, released data from a long-term clinical trial of Ocrevus in multiple sclerosis. Meanwhile, Novartis isn’t standing still on MS. Earlier this week the company announced that both the FDA and EMA had accepted its NDA and MAA, respectively, for siponimod.
-
Celgene Corporation presented data at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) held in Berlin, Germany with results from two Phase III trials.
-
A new biopharmaceutical company known as Sitryx launched with $30 million in a Series A funding round to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation.
-
In 2015, Priscilla Chan, a physician, and her husband, Facebook founder and CEO Mark Zuckerberg, created the Chan Zuckerberg Initiative (CZI). CZI’s stated goal was resoundingly ambitious.
-
September 14 Research Roundup: Brain in a Dish, Pathway Map for Diabetes, and “Finding Nemo’s” Ge...
9/14/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
Last year’s influenza season in the U.S. had record-breaking hospitalization rates. A lot of industry observers are looking at a new flu drug, baloxavir marboxil, for which clinical trial data was just published.
-
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”
-
CRISPR pioneer Jennifer Doudna has set up shop in San Francisco’s Gladstone Institutes. Doudna, a UC Berkley professor credited with the co-discovery of CRISPR-Cas9 genome editing technique, will focus on the development of new ways to implement the gene-editing technique for disease treatment.
-
Ambys Medicines, based in Redwood City, California, has launched in an unusual deal with Osaka, Japan’s Takeda Pharmaceutical Company.
-
The Cancer Prevention Institute of California (CPIC), located in Fremont, California, announced it was disbanding after 44 years. The reason for the closing, it indicates, is lack of federal funding.
-
Liver Fix Thyself
5/2/2018
By studying a rare liver disease called Alagille syndrome, scientists from Cincinnati Children's and the University of California San Francisco (UCSF) have discovered the mechanism behind an unusual form of tissue regeneration that may someday reduce the need for expensive and difficult-to-obtain organ transplants.
-
Automated Breast Density from Volpara Solutions Strongly Predicts Risk of Screen-Detected and Interval Cancers
5/1/2018
Research from University of California San Francisco and the Mayo Clinic Supports the Use of Fully Automated Volpara®Density™ Software to Inform Women of their Breast Density
-
Enamine Expands Collaboration with UCSF to Explore Synthetically Feasible Chemical Space
1/25/2018
Enamine today announced that it has expanded its collaboration on ZINC, a comprehensive online database of purchasable compounds curated by the Irwin and Shoichet laboratories in the Department of Pharmaceutical Chemistry at the University of California, San Francisco (UCSF).
-
Midatech and UCSF Receive IND Approval for DIPG Treatment MTX110
1/16/2018
The study will be conducted at leading treatment centres in UCSF in San Francisco, and the Memorial Sloan Kettering Cancer Center in New York
-
Apexigen Announces New Collaboration With UCSF
10/25/2017
Apexigen today announced the initiation of patient enrollment in a Phase II clinical trial in collaboration with the UCSF.
-
Strata Oncology Announces Partnership With UCSF To Launch Stratify Prostate Initiative To Expand Access To Precision Medicine Clinical Trials For 10,000 Men With Metastatic Prostate Cancer
10/4/2017
-
Novartis AG Lures Superstar Scientist Away From UCSF
8/17/2017